Showing results (211-220 of 274) with videos related to
Sort By:
Pageof 28
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2009
Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancerDavid Cunningham, Ian Chau, Deborah D Stocken, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2019
MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal CancerShelize Khakoo, Paul David Carter, Gina Brown, et al.British Journal of Cancer|September 14, 2016
Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumabCharles S Fuchs, Josep Tabernero, Jiří Tomášek, et al.The Lancet. Oncology|December 25, 2025
First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trialJong-Mu Sun, Yee Chao, Sung-Bae Kim, et al.JCO Oncology Advances|May 7, 2025
Maintenance Capecitabine Plus Ramucirumab After First-Line Chemotherapy in Patients With Advanced Esophagogastric Adenocarcinoma: Results From the Randomized PLATFORM StudyAnderley Gordon, David Cunningham, Zayn Rajan, et al.Leukemia & Lymphoma|November 10, 2017
Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie HospitalMary Gleeson, Clare Peckitt, David Cunningham, et al.Journal of Gastric Cancer|July 7, 2017
Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient DataCharles S Fuchs, Kei Muro, Jiri Tomasek, et al.The Lancet. Oncology|April 19, 2013
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trialTom Waddell, Ian Chau, David Cunningham, et al.Clinical Colorectal Cancer|July 26, 2018
Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal CancerRaghav Sundar, Susana Miranda, Daniel Nava Rodrigues, et al.Frontiers in Oncology|October 5, 2020
Diagnostic Accuracy and Safety of Coaxial System in Oncology Patients Treated in a Specialist Cancer Center With Prospective Validation Within Clinical Trial DataKhurum Khan, Reyes Gonzalez-Exposito, David Cunningham, et al.Pageof 28